LachnospiraceaeLachnospiraceaeLachnospiraceae flagellin. Also provided is antibody of fragment thereof that binds to one or more of the plurality of the flagellin peptides in the peptide array. The peptide array and antibody are useful in determining an immunosignature from a biological sample from a subject. The immunosignature is useful in diagnosis of an immune-mediated disease, in monitoring progression of an immune-mediated disease, in identifying subjects susceptible to certain treatments, and in monitoring treatment response.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
United States Government as Represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Slominski, Andrzej T.
Raman, Chander
Quayyum, Shariq
Abrégé
The present disclosure provides for pharmaceutical composition and methods of treating a condition using the pharmaceutical composition. The condition to be treated in a subject in need of treatment can include an infection or non-viral hyper-inflammation/immune hyperactivation condition. The infection can be a coronavirus infection, HIV infection, influenza infection, or the like, where a direct or indirect result of the infection can be respiratory distress, oxidative stress, and the like that can lead to acute respiratory distress syndrome (ARDS) and/or organ dysfunction or failure.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p.ex. prégnane ou progestérone
A61K 31/593 - Dérivés du 9,10-séco-cholestane, p.ex. cholécalciférol, vitamine D3
A61P 31/14 - Antiviraux pour le traitement des virus ARN
Provided herein are Mycobacterium smegmatis porin nanopores, systems that comprise these nanopores, and methods of using and making these nanopores. Such nanopores may be wild-type MspA porins, mutant MspA porins, wild-type MspA paralog porins, wild-type MspA homolog porins, mutant MspA paralog porins, mutant MspA homolog porins, or single-chain Msp porins. Also provided are bacterial strains capable of inducible Msp porin expression.
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 13/00 - Traitement de micro-organismes ou d'enzymes par énergie électrique ou ondulatoire, p.ex. par magnétisme, par des ondes sonores
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
4.
CATALYTIC NANOFIBER MEMBRANE ASSEMBLY AND REDUCED PRESSURE PLASMA REACTOR FOR FLUID, VAPOR AND GAS PROCESSING
Various examples are provided related to catalytic nanofiber membrane assemblies or structures which can be used in plasma reactors. In one example, a three-dimensional (3D) catalytic structure includes nanofiber-based elements (NFBEs) and electrodes placed about the NFBEs with the NFBEs stacked between the electrodes. In another example, a plasma reactor includes a vessel containing the 3D catalytic structure where gas pressure in the vessel is less than 1 atmosphere.
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
6.
SYSTEMS AND METHODS FOR GENERATING HISTORY AND PHYSICAL EXAM NOTES
A method for generating a medical record note comprises (i) accessing a corpus of medical documentation for a particular patient; (ii) receiving, at a user interface, chief complaint input indicating a chief complaint associated with the particular patient; (iii) utilizing (a) the chief complaint and (b) at least a portion of the corpus of medical documentation for the particular patient as input to a set of artificial intelligence (AI) modules, the set of AI modules being trained to generate medical record note output in response to medical documentation input; and (iv) generate a medical record note for the particular patient based on output of the set of AI modules.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
7.
METHODS FOR CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS
This invention includes methods for assessing and treating risk of cardiovascular disease (CVD) in a subject with an inflammatory disease, for example rheumatoid arthritis (RA). Provided are methods for assessing risk, for recommending therapy, for prognosis and monitoring, and for treatment, which are advantageously accurate for CVD in RA. The methods include measuring quantitative data for biomarkers, calculating a CVD risk score for a subject using training data, and validating the CVD risk score with a set of validation clinical data.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A disposable imaging phantom including a top housing having an inlet, and outlet, and first chamber in communication with the inlet and outlet and a bottom housing having a second chamber. The bottom housing connects to the top housing. The first and second chamber are configured to receive a first fluid. The first chamber is configured to receive a second fluid through the inlet to displace the first fluid through the outlet. The imaging phantom also includes a membrane assembly configured to be positioned between portions of the top and bottom housings. The membrane assembly includes a semi-permeable membrane configured to permit diffusion of the second fluid from the first chamber into the second chamber.
G01R 33/58 - Etalonnage des systèmes d'imagerie, p.ex. utilisant des sondes d'essai
G01R 33/563 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p.ex. angiographie à écoulement contrasté
9.
THREE-DIMENSIONAL CULTURE SYSTEM FOR GENERATING CARDIAC SPHEROIDS
Disclosed herein is a simple and reproducible 3D-culture-based process for generating cardiac spheroids containing all four cardiac-cell types (cardiomyocytes, endothelial cells, smooth muscle cells, and cardiac fibroblasts) that is compatible with a wide range of applications and research equipment. Subsequent experiments demonstrated that the inclusion of vascular cells and cardiac fibroblasts was associated with an increase in spheroid size, a decline in apoptosis, an improvement in sarcomere maturation and a change in CM bioenergetics. These suggest a three-dimensional (3D) environment with endothelial cells, smooth muscle cells, and cardiac fibroblasts which promoted CM maturation and electrical activity.
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
10.
COMPOSITIONS AND METHODS FOR TREATMENT OF SUBJECTS SUFFERING FROM A SARS-COV-2 INFECTION
The application is directed to methods for treatment or prevention of SARS-CoV-2 infection in a subject in need thereof, the composition comprising an organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically acceptable salt thereof, and methods of using the same.
The current disclosure provides methods for the production of 'vaccine-like' antiviral preparations. The present disclosure provides compounds for the treatment of a wide range of enveloped viral diseases and conditions. The present disclosure further provides methods for treating, preventing, and/or suppressing an enveloped virus disease in a subject using the compounds disclosed herein as well as pharmaceutical compositions comprising such compound.
In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antigen, wherein the CMV genome or portion thereof comprises a mutation within a interleukin-10-like gene sequence. Methods for preventing and treating diseases such as infectious diseases and cancer are also provided herein.
A method for co-registering imagery of different modalities includes accessing a first image captured according to a first imaging modality that depicts a plurality of physical markers. The plurality of physical markers is present within a scene represented in the first image. The method includes accessing a second image captured according to a second imaging modality that captures at least a portion of the scene including the plurality of physical markers. The method further includes generating a transformation matrix using the first image data and the second image data and generating an aligned image by applying the transformation matrix to the first image or the second image. The aligned image is combinable with the first image or the second image to generate co-registered image output. The co-registered image output depicts the portion of the scene according to the first imaging modality and the second imaging modality.
G06T 7/55 - Récupération de la profondeur ou de la forme à partir de plusieurs images
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images utilisant des procédés basés sur les caractéristiques
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p.ex. DICOM, HL7 ou PACS
A61B 6/00 - Appareils pour diagnostic par radiations, p.ex. combinés avec un équipement de thérapie par radiations
14.
SYSTEMS AND METHODS FOR DETERMINING IMAGING SUBJECT ORIENTATION
A system for determining subject orientation includes a medical imaging sensor configured to capture medical imagery of an imaging subject. The system also includes one or more interoceptive sensors, which are configured to obtain interoceptive sensor data indicative of an orientation associated with the system.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
16.
IDENTIFICATION OF NOVEL BENZOTHIAZONES AS TAU-SH3 INTERACTION INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, epilepsy, autism spectrum disorders, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 265/36 - Oxazines-1, 4; Oxazines-1, 4 hydrogénées condensés avec des carbocycles condensés avec un cycle à six chaînons
C07D 279/16 - Thiazines-1, 4; Thiazines-1, 4 hydrogénées condensés avec des carbocycles ou avec des systèmes carbocycliques condensés avec un cycle à six chaînons
A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
17.
Uracil Derivatives for Stimulating Read-Through of Premature Termination Codons
The present disclosure is concerned with substituted uracil compounds, pharmaceutical compositions comprising the compounds, and methods of treating disorders associated with the presence of a premature termination codon such as, for example, cystic fibrosis, Duchenne muscular dystrophy, aniridia, Becker muscular dystrophy, spinal muscular atrophy, Hurler syndrome, hemophilia, epidermolysis bullosa (e.g., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.
Symptoms of maladies originating in the same region of a brain can be treated with selective multifrequency stimulation. A first stimulation at a first frequency and a second stimulation at a second frequency can be generated by a signal generator. The first stimulation can be applied to a first location in the brain region to trigger an excitation period for a first set of neural elements in the brain region to treat at least one symptom of the malady. The second stimulation can be applied, after a time to ensure the first set of neural elements has entered a refractory period, to a second location in the brain region to trigger an excitation period for a second set of neural elements in the brain region to treat the at least one symptom and/or at least another symptom. The first set of neural elements is not excited by the second stimulation.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
20.
ENVIRONMENTAL EXPOSURE AND LUNG HEALTH MONITORING DEVICE
The present disclosure presents wearable sensor apparatuses, systems, and related methods. One such apparatus is in the form of a wearable sensor device that comprises a processor and a plurality of gas sensors integrated on the wearable sensor device, in which the gas sensors measure an amount of NO2, SO2, and O3 present in ambient air. The wearable sensor device further comprises a peak flow meter sensor integrated on the wearable sensor device; a temperature sensor integrated on the wearable sensor device; a GPS sensor integrated on the wearable sensor device; one or more transceivers integrated on the wearable sensor device; and an electronic display, wherein the processor is coupled to the electronic display and is operable to display sensor data measured from the wearable sensor device.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 40/60 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux
21.
METHODS RELATING TO DIAGNOSING STABILITY FOLLOWING RENAL TRANSPLANTATION
Clinical detection or diagnosis of transplant rejection currently utilizes various methods that rely on qualitative rather than quantitative data, or quantitative data that has low sensitivity and/or has a high rate of operator error. Provided herein are methods for identifying kidney transplant rejection in patents that is automated and consistent for the user. Further described herein are cut-offs for transplant biomarkers that relate to renal transplantation stability or rejection.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 16/24 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
22.
DEVICES AND METHODS FOR TRANSCUTANEOUS BILIRUBIN MEASUREMENT
Wearable devices for measuring health indicators such as bilirubin are provided. The device includes a skin-facing side including a circuit board. The circuit board includes a spectrometer integrated circuit, at least one light emitting diode (LED) configured to direct light at the subject's skin where the LED is operably connected to a power source, at least one photodetector configured to receive light reflected from the subject's skin, and a microcontroller configured to perform spectral subtraction of said reflected light.
G01N 33/72 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les pigments du sang, p.ex. l'hémoglobine, la bilirubine
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang en utilisant des capteurs optiques, p.ex. des oxymètres à photométrie spectrale
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
23.
TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE
The USA, as Represented by the Secretary, Department of Health and Human Service (USA)
Inventeur(s)
Hall, Matthew
Urban, Daniel J.
Knight, John
Holmes, Ross
Wood, Kyle David
Waterson, Alex
Darley-Usmar, Victor M.
Neckers, Leonard M.
Abrégé
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amount of compound of the formula
and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
24.
METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY SKIN DISORDERS
Provided herein are methods for treating or preventing inflammatory skin disorders, such as Hidradenitis suppurativa, by administering to a subject having or at risk of developing the inflammatory skin disorder an agent that inhibits NK cell activity.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 47/51 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification
25.
SAPONIN-BASED IMMUNOSTIMULANTS, PHARMACEUTICAL COMPOSITION COMPRISING SAID IMMUNOSTIMULANTS, THERAPEUTIC USE THEREOF
The present disclosure provides for compounds including modified saponin compounds, pharmaceutical compositions including modified saponin compounds, methods of use of the modified saponin compounds and the pharmaceutical compositions, methods of making modified saponin compounds, and the like. Compounds and pharmaceutical compositions of the present disclosure can be used in combination with one or more other therapeutic agents for treating viral infection and other diseases.
C07J 63/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par expansion d'un seul cycle par un ou deux atomes
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
26.
INHALED RESPIRATORY PROBIOTICS FOR LUNG DISEASES OF INFANCY, CHILDHOOD AND ADULTHOOD
The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
In one aspect, the disclosure relates to a synthetic modified mRNA (modRNA) and a novel gene therapy approach using the same that offers efficient, transient, safe, nonimmunogenic, and controlled mRNA delivery to the heart tissue without any risk of genomic integration. In a further aspect, the disclosure relates to methods of using the modRNA to achieve transient and exclusive overexpression of CCND2 only in cardiomyocytes, increasing cell cycle markers, enhancing cardiac function, and promoting myocardial repair. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
28.
SYSTEMS AND METHODS FOR PREVENTING ERRORS IN MEDICAL IMAGING
A method for preventing wrong-patient errors includes receiving a selection of a current imaging subject. The current imaging subject is selected for a current image acquisition session comprising capturing one or more current images of the current imaging subject utilizing at least a first image sensor system of a first imaging modality. The method includes accessing one or more previous images of a previous imaging subject. The one or more previous images depict the previous imaging subject according to at least a second imaging modality that is different from the first imaging modality. The method includes presenting the one or more previous images on a display system and, in response to determining that the previous imaging subject matches the current imaging subject based upon the one or more previous images, performing the current image acquisition session.
The United States Government as represented by the Department of Veterans Affairs (USA)
Inventeur(s)
Suto, Mark J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie M.
Abrégé
The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 215/48 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
C07D 217/22 - Composés hétérocycliques contenant les systèmes cycliques de l'isoquinoléine ou de l'isoquinoléine hydrogénée avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle contenant l'azote
Provided herein are NO generating systems, methods for generating NO for inhaled therapy, and methods of treating patients in need of inhaled NO. The systems can include a reaction vessel having a headspace for NO accumulation, a NO storage system, and a gas mixing chamber. NO gas generated in the reaction vessel can be delivered to the NO storage system via pressure generated by generation of the NO gas, then the NO gas is mixed with a carrier gas in a gas mixing chamber. NO can be generated at the point of patient delivery.
The present disclosure relates to techniques for anti-myopia visual display therapy using a simulated myopic blur. In one particular aspect, a method is provided that includes obtaining a pattern for a digital image, selecting a color channel of the digital image, applying a blur effect to the color channel that modifies the digital image to have a simulated blur, and providing anti-myopia visual display therapy to a subject using the modified digital image. The therapy comprises: (i) rendering the modified digital image on a display of a computing device within a visual environment of the subject, or (ii) placing the modified digital image within the visual environment of the subject, based on an optimal viewing time.
H04N 13/15 - Aspects des signaux d’images en rapport avec la couleur
A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
G06F 18/40 - Dispositions logicielles spécialement adaptées à la reconnaissance des formes, p.ex. interfaces utilisateur ou boîtes à outils à cet effet
H04N 13/128 - Ajustement de la profondeur ou de la disparité
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeux; Dispositifs pour mettre en place des verres de contact; Dispositifs pour corriger le strabisme; Appareils pour guider les aveugles; Dispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
32.
URACIL DERIVATIVES FOR STIMULATING READ-THROUGH OF PREMATURE TERMINATION CODONS
egg., dystrophic (DEB) form, junctional (JEB) form), Usher syndrome, and cancer, using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
The present disclosure relates to a method of detecting airflow obstruction using one or more novel metrics associated with a spirometry reading for a subject. The method includes obtaining spirometry data from a subject, generating a first measurement curve and a second measurement curve based on the obtained data for the subject, performing at least a first curve-fitting on the first measurement curve using a Least Absolute Residuals algorithm to estimate a function which closely approximates the spirometry data for the subject by minimizing a sum of absolute deviation, determining a first metric that describes a rate of volume increase based on the estimated function, comparing the first metric to one or more threshold values, and determining a presence or absence of airflow obstruction for the subject based on the comparison of the first metric to the one or more threshold values.
A61B 5/091 - Mesure du volume des gaz inspirés ou expirés, p.ex. pour déterminer la capacité pulmonaire
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients
34.
Compositions and Methods for Treatment and Prevention of Type 1 Diabetes
The invention relates to cells for adoptive cell therapy, e.g., adoptive immunotherapy. The cells include macrophages in which the iPLA2β gene is disrupted. Also provided are methods and uses of the cells, such as in adoptive therapy in the treatment or prevention of type 1 diabetes (T1D). Also provided are methods for engineering, preparing, and producing the cells, and compositions containing the cells. In some aspects, the provided embodiments provide an improved composition and method for the treatment of T1D. Among the cells disclosed herein are those in which certain genes and/or gene products have been disrupted, modified and/or repressed, in particular via disruption that impairs or reduces expression of iPLA2β.
CD206 targeted peptide conjugates are provided. Aspects of the conjugates include a CD206 binding peptide conjugated to a label or therapeutic agent. Also provided are methods of using the conjugates, e.g., in diagnostic or therapeutic applications.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p.ex. utilisation de bandes de papier indicateur
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
36.
CHEMICAL-BASED NITRIC OXIDE GAS-GENERATING DRUG DEVICE FOR DELIVERY TO A PATIENT
The present disclosure provides tracking systems and methods. One such method comprises generating a continuous wave signal over a frequency range; applying the continuous wave signal to a reading coil element that is electromagnetically coupled to a sensor array, wherein the sensor array comprises a plurality of sensing resonators tuned at different resonance frequencies, where an output frequency response of the sensor array varies as a function of a location of a target object or a shape of the target object within a coverage area of the sensor array; acquiring frequency spectrum data showing changes in the output frequency response of the sensor array from the reading coil element; and predicting, by a control unit device using machine learning, a location of the target object within the coverage area or a behavior of the target object based on the acquired frequency spectrum data. Other methods and systems are also provided.
G01D 5/14 - Moyens mécaniques pour le transfert de la grandeur de sortie d'un organe sensible; Moyens pour convertir la grandeur de sortie d'un organe sensible en une autre variable, lorsque la forme ou la nature de l'organe sensible n'imposent pas un moyen de conversion déterminé; Transducteurs non spécialement adaptés à une variable particulière utilisant des moyens électriques ou magnétiques influençant la valeur d'un courant ou d'une tension
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
G06N 5/02 - Représentation de la connaissance; Représentation symbolique
A01K 1/03 - Logements pour animaux domestiques ou de laboratoire
Epileptic seizures cannot be effectively controlled in many patients, thereby necessitating the development of novel therapeutic agents. Activation of the A1 receptor (A1R) by endogenous adenosine is an intrinsic mechanism to self-terminate seizures and protect neurons from excitotoxicity. However, targeting A1R for neurological disorders has been hindered by side effects associated with its broad expression outside the nervous system. Herein, the neural-specific A1R/neurabin/RGS4 complex that dictates A1R signaling strength and response outcome in the brain is targeted. A peptide was developed to block the A1R-neurabin interaction and enhance A1R activity. Anticonvulsant and neuroprotective effects are achieved through enhanced A1R function in response to endogenous adenosine in the brain, thus avoiding side effects associated with A1R activation in peripheral tissues and organs.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A method of optimizing vehicle mobility performance includes receiving technical parameters for each wheel associated with wheel power of the particular wheel on a particular terrain. The method includes determining an optimal vehicle mobility performance by determining an optimal tire slippage for one wheel based on the set of technical parameters for the wheel and individually determining an optimal tire slippage for another wheel based on the set of technical parameters for the other wheel. A system may utilize such a method to control mobility performance in a vehicle such as, but not limited to, an autonomous ground vehicle.
B60W 40/12 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés à des paramètres du véhicule lui-même
B60W 60/00 - Systèmes d’aide à la conduite spécialement adaptés aux véhicules routiers autonomes
B60W 40/02 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés aux conditions ambiantes
B60W 50/00 - COMMANDE CONJUGUÉE DE PLUSIEURS SOUS-ENSEMBLES D'UN VÉHICULE, DE FONCTION OU DE TYPE DIFFÉRENTS; SYSTÈMES DE COMMANDE SPÉCIALEMENT ADAPTÉS AUX VÉHICULES HYBRIDES; SYSTÈMES D'AIDE À LA CONDUITE DE VÉHICULES ROUTIERS, NON LIÉS À LA COMMANDE D'UN SOUS-ENSEMBLE PARTICULIER - Détails des systèmes d'aide à la conduite des véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier
A method of optimizing vehicle mobility performance includes receiving technical parameters for each wheel associated with wheel power of the particular wheel on a particular terrain. The method includes determining an optimal vehicle mobility performance by determining an optimal tire slippage for one wheel based on the set of technical parameters for the wheel and individually determining an optimal tire slippage for another wheel based on the set of technical parameters for the other wheel. A system may utilize such a method to control mobility performance in a vehicle such as, but not limited to, an autonomous ground vehicle.
G07C 5/02 - Enregistrement ou indication du temps de circulation, de fonctionnement, d'arrêt ou d'attente uniquement
B60W 40/10 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés au mouvement du véhicule
41.
COMPOSITIONS AND METHODS OF REGENERATING HEART TISSUES WITH AMINOGLYCOSIDES
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Sadek, Hesham A.
Nguyen, Ngoc Uyen Nhi
Ahmed, Mahmoud Salama
Tomchick, Diana
Zhang, Jianyi
Abrégé
Disclosures herein are directed to methods of regenerating cardiomyocytes in heart tissue damaged as a result heart failure in a subject by administering one or more aminoglycosides to a subject in need thereof. Accordingly, disclosures herein are also toward methods of administering one or more aminoglycosides to treat heart failure in a subject in need thereof.
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Suto, Mark, J.
Mathew, Bini
Augelli-Szafran, Corinne, E.
Yatchang, Marina, Fosso
Athar, Mohammad
Agarwal, Anupam
Srivastava, Ritesh Kumar
Muzaffar, Suhail
Khan, Jasim
Abrégé
The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/444 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. amrinone
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Various examples are provided related to blood-interface materials for metallic biomedical implants and devices. In one example, a bio-compatible implant or device includes an organosilane plasma polymerization (OPP) coating disposed on a surface of a metallic structure. The OPP coating can include inorganic silica disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a biocompatible implant or device includes a composite coating disposed on a surface of the metallic structure. The composite coating can include silica-DEA, silica-MEA or silica-TEA coating disposed on bare metal of the metallic structure and forming a nano-textured surface. In another example, a method includes providing a metallic structure and exposing it to an OPP process to form a coating on the surface of the metallic structure to form the bio-compatible implant or device.
A61L 29/12 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
For many proteins, aggregation starts from phase separation, which frequently results from intermolecular interactions mediated by disordered protein regions. These disordered regions often contain repetitive sequences (also known as low-complex regions). In some embodiments, the protein solubilizing method described herein is applicable for proteins with the following two classes of repetitive sequences. Disclosed herein are mimic peptide sequences > 3 amino acids that can increase protein solubility of proteins having disordered protein regions.
A61K 38/00 - Préparations médicinales contenant des peptides
C07C 323/60 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des groupes carboxyle liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné avec l'atome de carbone d'au moins un des groupes carboxyle lié à des atomes d'azote
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
The Board of Trustees of the University of Alabama (USA)
THE UAB RESEARCH FOUNDATION (USA)
Inventeur(s)
Sazonov, Eduard S.
Salas, Ariel A.
Chandler-Laney, Paula Catherine
Abrégé
A feeding bottle includes a bottle enclosure defining a hollow bottle chamber, wherein the enclosure defines a feeding outlet at a first end and an attachment structure 26 at a second end. A bottom housing defines an instrument compartment extending between a closed exterior portion of the bottom housing and a separation surface within the bottom housing, wherein the bottom housing is configured for detachable connection to the attachment structure 26 of the bottle enclosure. A relief valve is positioned within the separation surface of the bottom housing. A pressure sensor is positioned adjacent the separation surface of the bottom housing and connected by a passageway to the instrument compartment in the bottom housing, wherein the pressure sensor is configured to detect changes of pressure in the bottle enclosure.
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
Described herein are Dendrilla membranosa compounds and derivatives thereof. Also described herein are formulations that can contain an amount of one or more Dendrilla membranosa compounds or derivatives thereof and a carrier. Also described herein are methods of administering one or more Dendrilla membranosa compound and/or derivative thereof or a formulation thereof to a subject in need thereof.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
51.
RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Nabors, Louis B.
Filippova, Natalia
Yang, Xiuhua
Ananthan, Subramaniam
Pathak, Vibha
King, Peter
Abrégé
This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present disclosure describes system and methods for determining cardiac events from a physiological data signal and optionally constructing a Pressure-Volume (PV) loop display from non-simultaneously acquired measurements of pressure and volume data. One such method comprises obtaining, by a computing device, a physiological data signal of a heart of an individual; identifying, by the computing device, features of the physiological data signal and applying the features as inputs to a prediction model; determining, by the computing device using the prediction model, the cardiac events for one or more valves of the heart, wherein the cardiac events include timing of opening and closing of the one or more valves of the heart; and outputting, by the computing device, the cardiac events determined using the prediction model. The physiological data signal can be combined with non-simultaneously acquired volume data to create a PV loop display.
Relationships between morphological changes to an eye due to intraocular pressure changes and blood perfusion and nerve function changes in the retina are determined by colocalizing retinal perfusion data, optic nerve head (ONH) mechanical deformation data, visual field data and nerve fiber data. Perfusion and nerve function changes from intraocular pressure (IOP) changes are determined by colocalizing retinal perfusion data with ONH mechanical deformation data, visual field data and nerve fiber data. Optical coherence tomography-angiography (OCT-A) can be used to generate retinal perfusion data, mechanical deformation data for an imaged volume, and nerve fiber data. A three-dimensional model (e.g., connectivity map or connectivity model) of the vasculature and nerve fibers can be generated from the OCT-A imaging data and used to predict changes in blood perfusion and nerve function in various areas of the retina due to IOP-induced mechanical deformations.
A61B 3/12 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p.ex. ophtalmoscopes
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
G06T 7/33 - Détermination des paramètres de transformation pour l'alignement des images, c. à d. recalage des images utilisant des procédés basés sur les caractéristiques
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
54.
METHODS AND FORMULATIONS RELATED TO THE INTRATHECAL DELIVERY OF ONCOLYTIC VIRUSES
A method of treating a central nervous system cancer in a subject comprising administering to the subject a preconditioning agent, and, administering to the subject a therapeutic dose of an oncolytic virus; wherein the preconditioning agent is an immunostimulant selected from the group consisting of a toll-like receptor agonist, a subtherapeutic dose of an oncolytic virus, and/or an interferon that induces a transient anti-viral response and/or upregulates an interferon response; and wherein the preconditioning agent and the therapeutic dose of the oncolytic virus is administered to the subject's cerebrospinal fluid or periependymal region. Provided herein are methods of treating a central nervous system cancer in a subject. This method allows for intrathecal administration of oncolytic virus, which, until the present invention, resulted in unacceptable toxicity.
In one aspect, the disclosure relates to nanoparticle compositions including TT-10 or a pharmaceutically acceptable salt thereof and nanoparticles including at least one biocompatible polymer or copolymer such as poly-lactic-co-glycolic acid. Also disclosed are methods for improving at least one cardiac function or property following heart damage in a subject, the methods including at least the step of administering the nanoparticle compositions to the subject. In another aspect, the nanoparticle compositions can be administered by intraperitoneal injection and are active at a target site for a period of at least 4 weeks.
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
Disclosed is a method for reducing metastasis and/or tumor growth in a subject with cancer by administering an effective amount of an inhibin antibody to the subject with cancer. In particular, the subject may have ovarian cancer and the administration of inhibin antibody may impair tumor growth.
Methods for using BMP9 or an agonist thereof to reduce metastasis of cancer are disclosed. The method may include administering an effective amount of BMP9 or an agonist thereof to a subject in need thereof, to reduce metastasis of cancer. The subject may be a human.
In one aspect, the disclosure relates to a method for treating or preventing at least one symptom of exposure to a toxic gas such as chlorine, bromine, or phosgene in a subject, the method including administering a composition containing AMD3100 or a pharmaceutically acceptable salt thereof to the subject. In one aspect, the composition can be administered by intramuscular injection, intranasally, or by inhalation in an amount of from about 0.01 to about 0.25 mg of AMD3100 per kg of subject body weight.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 47/18 - Amines; Amides; Urées; Composés d’ammonium quaternaire; Acides aminés; Oligopeptides ayant jusqu’à cinq acides aminés
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
59.
CONTROL OF SUBUNIT STOICHIOMETRY IN SINGLE-CHAIN MSP NANOPORES
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 15/31 - Gènes codant pour des protéines microbiennes, p.ex. entérotoxines
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
60.
METHODS FOR PREVENTION OF GRAFT REJECTION IN XENOTRANSPLANTATION
The present invention relates to methods, treatment regimens, uses, kits and therapies for prevention of graft rejection in solid organ transplantation, particularly solid organ xenotransplantation, by administering an anti-CD40 antibody or a combination of an anti-CD40 antibody and an anti-C5 antibody.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
61.
HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF
The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.
C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
62.
Methods of Treatment of Neurofibromatosis Type 1 (NF1) and NF-1 Mediated Conditions and Compositions for Use in Such Methods
Royal Holloway and Bedford New College, (Royaume‑Uni)
Inventeur(s)
Wallis, Deeann
Kesterson, Robert
Korf, Bruce
Leier, Andre
Lambert, Laura
Popplewell, Linda
Dickson, George
Abrégé
The present disclosure provides methods and compositions for the treatment of NF-1 and NF-1 mediated conditions. The present disclosure further provides for methods of exon skipping and exon retention and compositions for use in such methods. Such methods of exon skipping and exon retention may be used in the methods of treatment discussed herein. The present disclosure further provides new therapeutic compounds, particularly oligonucleotides, including antisense oligonucleotides, for use in the methods described herein.
Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A method for preventing wrong-patient errors includes receiving a selection of a current imaging subject. The current imaging subject is selected for a current image acquisition session comprising capturing one or more current images of the current imaging subject utilizing at least a first image sensor system of a first imaging modality. The method includes accessing one or more previous images of a previous imaging subject. The one or more previous images depict the previous imaging subject according to at least a second imaging modality that is different from the first imaging modality. The method includes presenting the one or more previous images on a display system and, in response to determining that the previous imaging subject matches the current imaging subject based upon the one or more previous images, performing the current image acquisition session.
A coil wire and method of using the coil wire to navigate blood vessels are provided. The coil wire is configured to facilitate coaxial catheter advancement over at least a part of the length of the coil wire. Existing catheters utilize the distal tip of a guidewire to select the vessel origins by shaping it (either during fabrication or by the operating physician) in such a way that the tip will point into the desired vessel as the wire is advanced. The coil wire of the present disclosure functions in a unique manner: its distal tip resumes a pre-formed three-dimensional coil configuration as it is expressed from the catheter. This shape catches the flow of moving blood and propels the coil wire forward while unfurling the coil. As the coil wire is advanced, the small outer diameter of the unfurled coil allows it to pass deep into the selected vessel.
The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that arc engineered to express a CTX-CAR described herein.
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A61K 31/192 - Acides carboxyliques, p.ex. acide valproïque ayant des groupes aromatiques, p.ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
68.
COMBINATION THERAPY WITH GLUCARPIDASE WITH METHOTREXATE/RITUXIMAB TO TREAT CNS LYMPHOMA
The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.
Provided is a modular offloading walker that offloads strain from a lower limb or foot. The walker includes a modular upper component and a modular lower component. The upper component can include a modular anterior component and a modular posterior component. The lower component includes a foot plate having a rocker sole and upright stays coupled to medial and lateral edges of the foot plate. The upright stays can have an adjustable height and the upper component can be removably attached to the upright stays.
A combination of herbal extracts and a probiotic supplement and formulated as a dietary supplement helps mitigate symptoms of bronchopulmonary disease in conjunction with the anti-inflammatory mechanisms of the probiotics. Provided are embodiments of a probiotic nutraceutical composition that delivers 3 strains of Lactobacillus spp. to the gut lining of human subjects to reduce neutrophilic inflammation as a result of or causative agent of bronchopulmonary disease. In addition to the three Lactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.
Lactobacillus sppLactobacillus sppLactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.
A combination of herbal extracts and a probiotic supplement and formulated as a dietary supplement helps mitigate symptoms of bronchopulmonary disease in conjunction with the anti-inflammatory mechanisms of the probiotics. Provided are embodiments of a probiotic nutraceutical composition that delivers 3 strains of Lactobacillus spp. to the gut lining of human subjects to reduce neutrophilic inflammation as a result of or causative agent of bronchopulmonary disease. In addition to the three Lactobacillus spp. strains, the compositions can include herbal extracts from holy basil, turmeric, and vasaka for respiratory relief.
A urine collection device is provided. The urine collection device includes a basin configured to fit a perineal region of a female human subject and to receive urine; a lip attached to the basin and having a contact surface for attachment to the perineal region; a ridge extending into the basin and disposed along an inferior portion of the lip to prevent leakage of urine from the basin; and a drain opening in the basin for draining the urine. The urine collection device advantageously prevents leakage and allows for easy access for urine analysis and measurement of urine output. Methods and systems for collecting and quantifying urine are also provided.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
A61F 5/455 - Réceptacles génitaux pour recueillir l'urine ou d'autres sécrétions des organes féminins
74.
MULTI-LAYERED NANOPARTICLE COATED SUBSTRATES FOR DRUG DELIVERY
Disclosed herein are bilayered substrates useful for treating infection and/or inflammation in a subject such as, for example, the upper respiratory system. In another aspect, the layers of the substrates disclosed herein include biocompatible and biodegradable polymers as well as one or more bioactive agents useful for treating infection and/or inflammation. In a further aspect, the layers of the substrate can contain nanoparticles incorporating the bioactive agents. In any one of the above aspects, the bioactive agents are released at a constant rate over a period of time. In still another aspect, the substrates disclosed herein are useful for reducing the mass of biofilms and reducing or preventing inflammation by inhibiting the production of interleukin-8.
Techniques for a pin-point assessment of resilience and resistance of structures against flooding are disclosed. The model is based on dimensionless analytical functions related to the variation of functionality during a period of interest, including the losses in the disaster and the recovery path. This evolution in time including recovery differentiates the resilience approach from the other approaches addressing the loss estimation and their momentary effects. The recovery process is considered to be dependent on societal preparedness, public policies and can take different forms, which is estimated using recovery functions. Based on the resilience, action plans are created to improve resiliency to disasters.
E04H 9/14 - Bâtiments, groupes de bâtiments ou abris conçus pour résister à des situations extérieures anormales, p.ex. à des bombardements, à des séismes ou à des climats extrêmes, ou pour se protéger de ces situations contre d'autres influences dangereuses, p.ex. tornades, crues
E02B 3/10 - Barrages; Digues; Canaux à vannes ou autres ouvrages pour digues, barrages ou analogues
Disclosed are various approaches for estimating uncertainty in deep neural networks. A respective tensor normal distribution can be applied to each of a plurality of convolutional kernels of a convolutional neural network, wherein the respective tensor normal distribution captures a correlation and a variance heterogeneity of each of the plurality of convolutional kernels. Then, the mean and covariance of each respective tensor normal distribution passing through the non-linear activation function of each nonlinear perceptron can be approximated. Next, a max-pool operation can be performed on a plurality of outputs of the plurality of non-linear perceptrons to generate an output tensor. Then, the output tensor can be vectorized to create an input vector for a fully-connected layer of the convolutional neural network. Subsequently, an output vector can be generated using the fully-connected layer. Then, a mean matrix and a covariance matrix for the output vector can be computed.
Hemopexin, salubrinal, aurothioglucose, and nitrite find uses in treating pulmonary injury from several causes, alone and in combination. Methods of treatment, methods of prevention, and pharmaceutical compositions are provided with those components.
A method of improving emmetropization or slowing myopia development in an eye is provided that involves adjusting the vision in the eye to achieve one or both of increase the distance between the long-wavelength focal plane and the short wavelength focal plane; and position the short wavelength focal plane closer to the cornea than it would normally be located. Multi-spectral devices (e.g., lenses and spectacles) are provided that are useful to improve emmetropization or preventing or reducing the development of myopia, which are optionally multi-focal as well.
University of Pittsburgh - Of the Commonwealth System of Higher Education (USA)
The UAB Research Foundation (USA)
Inventeur(s)
Rose, Jason Joseph
Gladwin, Mark Thomas
Patel, Rakesh P.
Matalon, Sadis
Abrégé
Methods for the treatment of lung injury caused by chemical inhalation, smoke inhalation or microbial infection are described. The methods include administering a therapeutically effective amount of nitrite or a nitrite formulation. Nitrite formulations that include a nitrite salt and an anti-caking agent, such as sodium bicarbonate, and the use of such formulations, is also described.
An AI system and method are provided that enable more accurate and efficient medical impressions to be automatically generated from reports of medical findings. The AI system and method automatically generate a summary, or impression, of a medical report from digitized text-based findings entered by a clinician. A user who may or may not be the person who generated the report of medical findings designates a medical professional who will be finalizing the report. The AI system selects the AI model that is associated with the medical professional who has been designated and uses the AI model to generate the impression section of the report.
G06F 7/00 - Procédés ou dispositions pour le traitement de données en agissant sur l'ordre ou le contenu des données maniées
G06F 17/00 - TRAITEMENT ÉLECTRIQUE DE DONNÉES NUMÉRIQUES Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des fonctions spécifiques
University of Florida Research Foundation, Incorporated (USA)
The UAB Research Foundation (USA)
Inventeur(s)
Zolotukhin, Sergei
Boye, Sanford L.
Boye, Shannon E.
Marsic, Damien
Gamlin, Paul D.
Abrégé
Adeno associated viral (AAV) particles are emerging as a useful vehicle for gene delivery to various organs and tissues, one of them being the retina. Provided here are variant AAV (for example, variant serotype 2 (AAV2)) capsid proteins and variant capsid protein containing particles with enhanced ability to transduce retinal cells.
The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of γδ T cell expansion and as T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p.ex. rapamycine
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p.ex. phosphate de pyridoxal
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12N 5/0783 - Cellules T; Cellules NK; Progéniteurs de cellules T ou NK
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
84.
COMPOSITIONS AND METHODS FOR UPREGULATION OF HUMAN FETAL HEMOGLOBIN
Provided herein are compositions and methods for increasing fetal hemoglobin in a subject in need thereof. Also provided are compositions and methods for treating a hemoglobin disorder in a subject.
A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
An AC-electrospinning system and a method are provided for fabricating inorganic fiber tubular structures. The AC-electrospinning system preferably uses an electrode system that comprises an electrical charging component electrode and at least one of an AC field attenuating component and a precursor liquid attenuating component. Use of the AC-electrospinning process to fabricate the inorganic fiber tubular structures allows the structures to be made with high porosities that are not achievable using the conventional approach.
D01D 5/00 - Formation des filaments, fils ou similaires
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
86.
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
VANDERBILT UNIVERSITY (USA)
THE UAB RESEARCH FOUNDATION (USA)
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventeur(s)
Maloney, David J.
Waterson, Alex Gregory
Bantukallu, Ganesh Rai
Brimacombe, Kyle Ryan
Christov, Plamen
Dang, Chi V.
Darley-Usmar, Victor
Hu, Xin
Jadhav, Ajit
Jana, Somnath
Kim, Kwangho
Kouznetsova, Jennifer L.
Moore, William J.
Mott, Bryan T.
Neckers, Leonard M.
Simeonov, Anton
Sulikowski, Gary Allen
Urban, Daniel Jason
Yang, Shyh Ming
Abrégé
Provided is a compound of formula (I)
1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/422 - Oxazoles non condensés et contenant d'autres hétérocycles
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p.ex. rifampine, thiothixène
A61K 31/501 - Pyridazines; Pyridazines hydrogénées non condensées et contenant d'autres hétérocycles
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5355 - Oxazines non condensées contenant d'autres hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p.ex pilocarpine, nitrofurantoïne
87.
SYSTEMS AND METHODS FOR DETECTION AND STAGING OF PULMONARY FIBROSIS FROM IMAGE-ACQUIRED DATA
A method for ascertaining pulmonary fibrosis disease progression or treatment response includes obtaining a first set of computed tomography (CT) images of a lung and determining a first Pulmonary Surface Index (PSI) score for the lung by detecting a first actual lung boundary of the lung within the first set of CT images, determining a first approximated lung boundary within the first set of CT images, and determining the PSI score using inputs based on the first actual lung boundary and the first approximated lung boundary. The method also includes obtaining a second set of CT images of the lung and determining a second PSI score for the lung using inputs based on a second actual lung boundary and a second approximated lung boundary. The method also includes assessing pulmonary fibrosis treatment response or disease progression based on the first PSI score and the second PSI score.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.
A surgical tool support system is provided. The system includes a support portion, a swivel arm, and a tool holder for holding a surgical tool coupled to a distal end of the swivel arm. The tool holder can have a locking joint controlled by an actuator such that the tool holder can be locked into a position along multiple axes of rotation. The system can offset the force required by a user to move the surgical tool, thereby reducing fatigue.
A computer-implemented method for facilitating opportunistic screening for cardiomegaly includes obtaining a set of computed tomography (CT) images. The set of CT images captures at least a portion of a heart of a patient, and the set of CT images is captured for a purpose independent of assessing cardiomegaly. The method further includes using the set of CT images as an input to an artificial intelligence (AI) module configured to determine a heart measurement based on CT image set input. The method also includes obtaining heart measurement output generated by the AI module and, based on the heart measurement output, classifying the patient into one of a plurality of risk levels for cardiomegaly. The classification is operable to trigger additional action based on the corresponding risk level for the patient.
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
92.
METHOD FOR DETECTING RADIOLOGICAL PROGRESSION IN CANCER SURVEILLANCE
A method and computer-based system is provided that assists physicians in detecting early tumor growth and allowing modification of treatment to have a positive impact on medical management, patient morbidity, outcomes and survival times. The method comprises measuring tumor volumes from radiological images to predict growth by a statistical method. The methods allow detection of increases in tumor size earlier than is currently possible and, therefore, advantageous in modifying or optimizing treatment.
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07K 14/35 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Suto, Mark J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie M.
Abrégé
The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Suto, Mark, J.
Mathew, Bini
Agarwal, Anupam
Traylor, Amie, M.
Abrégé
The present disclosure is concerned with biaryl aminomaleimide compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases ( e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
C07D 207/02 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
C07D 207/18 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique
C07D 207/444 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant deux atomes d'oxygène liés directement en positions 2 et 5 par une double liaison
96.
COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE
e.ge.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/472 - Isoquinoléines non condensées, p.ex. papavérine
C07D 215/02 - Composés hétérocycliques contenant les systèmes cycliques de la quinoléine ou de la quinoléine hydrogénée ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle
A number of MS- and natural-saponin-based vaccine adjuvant candidates have been prepared. The MS derivatives were prepared by incorporating a terminal-functionalized side chain into the C3 glucuronic acid unit of the natural saponins MS I and II through amide formation reaction; and the QS analogs were prepared via multi-step organic synthesis. These unnatural saponins showed significantly different immunostimulant activity profiles, suggesting that the structure of side chain, triterpenoid core, and oligosaccharide domain together orchestrate each saponin's characteristic potentiation of immune responses.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/26 - Hydrates de carbone, p.ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharides; Leurs dérivés, p.ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
98.
METHODS AND COMPOSITIONS FOR IL10 SIGNALING ANTAGONISM
This invention relates to fusion proteins, nucleic acid molecules, DNA constructs, and pharmaceutical compositions comprising the same, and methods of their use in IL10 antagonism.
An electrode system for use in an AC-electrospinning process comprises an electrical charging component electrode and at least one of an AC field attenuating component and a precursor liquid attenuating component. The electrical charging component electrode is electrically coupled to an AC source that places a predetermined AC voltage on the electrical charging component electrode. In cases in which the electrode system includes the AC field attenuating component, it attenuates the AC field generated by the electrical charging component electrode to better shape and control the direction of the fibrous flow. In cases in which the electrode system includes the precursor liquid attenuating component, it serves to increase fiber generation, even if the top surface of the liquid precursor is not ideally shaped or is below a rim or lip of the reservoir that contains the liquid on the electrical charging component electrode.
Disclosed are novel treatments for diseases and conditions caused by, directly or indirectly, high blood glucose levels increased gluconeogenesis. Such disease and conditions include, but are not limited to, type II diabetes, obesity, and cardiovascular conditions. Sam68, an RNA-binding adaptor protein and Src kinase substrate, is a novel regulator of hepatic gluconeogenesis and global and hepatic deletions of Sam68 significantly reduce blood glucose levels and the glucagon-induced expression of gluconeogenic genes. The treatments described herein may include inhibition of the activity of Sam68.